INSMED Q2 FY26 earnings call INSM

BRINSUPRI's launch continues at a historic pace, delivering $309.2 million in revenue in its third full quarter, a 49% sequential increase. The company raised its full-year 2026 revenue guidance for BRINSUPRI to $1.25 billion - $1.4 billion, reflecting robust demand and better-than-expected gross-to-net dynamics. New patient starts reached approximately 7,000 in Q2, exceeding prior expectations, and are projected to remain at this level for the rest of 2026. Cumulative prescribers increased to over 6,300, with 30% prescribing for at least 5 patients, indicating deepening adoption.

TPIP is emerging as a potentially differentiated asset across four large indications: PH-ILD, PAH, PPS, and IPF. Positive 12-month data from the ongoing open-label extension study in PAH patients showed sustained or improved efficacy across all measures, including a 55-meter improvement in 6-minute walk distance and a 60% reduction in NT-proBNP. The data also demonstrated a low 15% rate of treatment-emergent cough and a high 91% continuation rate. The company raised TPIP's peak sales estimate to over $6 billion, assuming clinical and regulatory success in all four indications and a profile comparable to sotatercept.

ARIKAYCE continues to perform well in its eighth year of launch, growing globally by high single digits this quarter, with $116.3 million in revenue. The company is progressing towards a potential label expansion from refractory MAC to all MAC lung disease in the U.S. and Japan. A supplemental new drug application (sNDA) was submitted to the FDA for newly diagnosed patients, and an application to Japanese regulators is planned for H2 2026, targeting potential launches in 2027. This expansion is expected to leverage synergies with BRINSUPRI's call points.

Insmed is steadily progressing a broad and diversified early-stage pipeline. The FDA recently cleared the IND for INS1033, a next-generation DPP1 inhibitor, with the first planned indication in rheumatoid arthritis, followed by ulcerative colitis and COPD. The company also strengthened its leadership team with the hiring of Samuele Butera as SVP and General Manager of Global Respiratory therapeutic area, bringing extensive commercial experience for global launches.

The company maintains a strong financial position with approximately $1.2 billion in cash, cash equivalents, and marketable securities as of Q2 2026. This reflects a lower burn rate due to higher revenue generation and financial discipline. Insmed expects to reach cash flow positivity in 2027 without raising additional capital, despite planned increased investments in TPIP Phase III programs, BRINSUPRI DTC advertising, and Japan commercial infrastructure. The long-term financial profile is expected to show compelling top and bottom-line growth well into the 2030s, driven by a synergistic portfolio of respiratory assets.

While Japan is a key focus for BRINSUPRI and ARIKAYCE launches, with strong team capabilities and planned sales force expansion, the European market presents challenges. The lack of willingness from European countries to pay for innovation due to budget constraints makes a traditional commercial approach less attractive. Insmed is exploring alternative ways to bring BRINSUPRI to appropriate patients in Europe, acknowledging the reduced attractiveness of the market compared to the past.

BRINSUPRI's strong performance is supported by favorable patient metrics, including high persistence, refill timing, and adherence rates, tracking ahead of internal benchmarks. The 7,000 new patient starts in Q2 were entirely organic demand. The company is focused on increasing prescribing depth, noting that while 30% of prescribers have written for at least 5 patients, there is significant room for growth, especially among Tier 1 physicians who treat over 100 patients each. Educational efforts and real-world data generation are underway to solidify BRINSUPRI's position.